Achieving durable CMR with an IFN-based therapy and potentially further combining with another effective approach such as a JAK2 inhibitor to significantly promote TFR and OS (Fig. 2), represents a paradigm shift in the current management of PV toward curative treatment. This evidence concerns the gene JAK2 and acquired polycythemia vera.